Merck's Keytruda Data Brighten Picture For PD-1 Inhibitors In Myeloma
This article was originally published in Scrip
Executive Summary
Data for Merck & Co. Inc.'s Keytruda (pembrolizumab) suggest a potential role for PD-1/L1 inhibitors as part of combinations in multiple myeloma, despite disappointing results in this indication in the past and an increasingly crowded treatment landscape.